Inovio Pharmaceuticals (NASDAQ:INO) Raised to “Sell” at StockNews.com

Inovio Pharmaceuticals (NASDAQ:INO) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Friday.

Several other brokerages have also recently issued reports on INO. Royal Bank of Canada decreased their price objective on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research note on Wednesday. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research note on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Inovio Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $12.20.

Inovio Pharmaceuticals Stock Down 1.0 %

Inovio Pharmaceuticals stock opened at $1.92 on Friday. Inovio Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $14.75. The firm has a market cap of $50.11 million, a PE ratio of -0.48 and a beta of 0.92. The company’s 50 day moving average is $2.04 and its two-hundred day moving average is $3.69.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.18. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.03 million. On average, equities research analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 3,630 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares in the last quarter. Alpine Global Management LLC purchased a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at $31,000. Atom Investors LP acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth $103,000. Finally, Bank of Montreal Can purchased a new stake in Inovio Pharmaceuticals in the fourth quarter valued at $43,000. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.